Malarone Pediatric Patent Expiration

Malarone Pediatric is a drug owned by Glaxosmithkline. It is protected by 6 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 25, 2014. Details of Malarone Pediatric's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6291488

(Pediatric)

Preventing protozoal infections
May, 2014

(10 years ago)

Expired
US5998449

(Pediatric)

Combination of atovaquone with proguanil for the treatment of protozoal infections
May, 2014

(10 years ago)

Expired
US6166046

(Pediatric)

Combination of atovaquone with proguanil for the treatment of protozoal infections
May, 2014

(10 years ago)

Expired
US5998449 Combination of atovaquone with proguanil for the treatment of protozoal infections
Nov, 2013

(11 years ago)

Expired
US6291488 Preventing protozoal infections
Nov, 2013

(11 years ago)

Expired
US6166046 Combination of atovaquone with proguanil for the treatment of protozoal infections
Nov, 2013

(11 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Malarone Pediatric is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Malarone Pediatric's family patents as well as insights into ongoing legal events on those patents.

Malarone Pediatric's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Malarone Pediatric's generic launch date based on the expiry of its last outstanding patent is estimated to be May 25, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Malarone Pediatric Generic API suppliers:

Atovaquone; Proguanil Hydrochloride is the generic name for the brand Malarone Pediatric. 2 different companies have already filed for the generic of Malarone Pediatric, with Glenmark Pharms Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Malarone Pediatric's generic

How can I launch a generic of Malarone Pediatric before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Malarone Pediatric's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Malarone Pediatric's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Malarone Pediatric -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
62.5 mg/25 mg 14 Sep, 2010 1 27 May, 2014 25 Nov, 2013 Extinguished
250 mg/100 mg 03 Apr, 2009 1 12 Jan, 2011 25 Nov, 2013 Eligible

Alternative Brands for Malarone Pediatric

Malarone Pediatric which is used for treating protozoal infections., has several other brand drugs in the same treatment category and using the same active ingredient (Atovaquone; Proguanil Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Glaxosmithkline
Malarone

(uses Atovaquone; Proguanil Hydrochloride)

Used for treating protozoal infections.

Apart from brand drugs containing the same ingredient, some generics have also been filed for Atovaquone; Proguanil Hydrochloride, Malarone Pediatric's active ingredient. Check the complete list of approved generic manufacturers for Malarone Pediatric





About Malarone Pediatric

Malarone Pediatric is a drug owned by Glaxosmithkline. It is used for treating protozoal infections. Malarone Pediatric uses Atovaquone; Proguanil Hydrochloride as an active ingredient. Malarone Pediatric was launched by Glaxosmithkline in 2000.

Approval Date:

Malarone Pediatric was approved by FDA for market use on 14 July, 2000.

Active Ingredient:

Malarone Pediatric uses Atovaquone; Proguanil Hydrochloride as the active ingredient. Check out other Drugs and Companies using Atovaquone; Proguanil Hydrochloride ingredient

Treatment:

Malarone Pediatric is used for treating protozoal infections.

Dosage:

Malarone Pediatric is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
62.5MG;25MG TABLET Prescription ORAL